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Dominant-negative mutations in the transcription factor GrowthFactor Independence-1B (GFI1B), such as GFI1BQ287*, cause a bleed-ing disorder characterized by a plethora of megakaryocyte and
platelet abnormalities. The deregulated molecular mechanisms and path-
ways are unknown. Here we show that both normal and Q287* mutant
GFI1B interacted most strongly with the lysine specific demethylase-1 –
REST corepressor - histone deacetylase (LSD1-RCOR-HDAC) complex in
megakaryoblasts. Sequestration of this complex by GFI1BQ287* and chemical
separation of GFI1B from LSD1 induced abnormalities in normal megakary-
ocytes comparable to those seen in patients. Megakaryocytes derived from
GFI1BQ287*-induced pluripotent stem cells also phenocopied abnormalities
seen in patients. Proteome studies on normal and mutant-induced pluripo-
tent stem cell-derived megakaryocytes identified a multitude of deregulated
pathways downstream of GFI1BQ287* including cell division and interferon
signaling. Proteome studies on platelets from GFI1BQ287* patients showed
reduced expression of proteins implicated in platelet function, and elevated
expression of proteins normally downregulated during megakaryocyte dif-
ferentiation. Thus, GFI1B and LSD1 regulate a broad developmental pro-
gram during megakaryopoiesis, and GFI1BQ287* deregulates this program
through LSD1-RCOR-HDAC sequestering.
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ABSTRACT
Introduction
Platelets are specialized cell fragments that function to prevent excessive bleeding
upon blood vessel injury.1 During megakaryopoiesis, megakaryoblasts undergo
endomitosis followed by cytoplasmic maturation, during which a- and δ-granules
are formed. Subsequently, mature megakaryocytes migrate to blood vessels in the
bone marrow or lung, where they form protrusions and shed proplatelets into the
bloodstream.2,3
The identification of inherited bleeding and platelet disorder mutations has pro-
vided insight into proteins crucial for platelet production and function. Genes
mutated in these disorders range from those encoding proteins involved in a-gran-
ule biology, such as NBEAL2, to transcription factors controlling a wide range of
megakaryocyte processes.4 One of the transcription fac-
tors mutated in inherited bleeding and platelet disorders is
Growth Factor Independence 1B (GFI1B). To date, truncat-
ing mutations affecting DNA binding,5-8 missense muta-
tions,9-11 and mutations that change the amount and ratio
of the two naturally occurring GFI1B isoforms (p37 and
p32) have been described.11,12 Bleeding tendencies may
vary depending on the type of mutations, being severe for
cases that express only GFI1B-p32,12 moderate to severe
for dominant-negative truncating mutations,5-8 and mild to
even absent for the missense mutations.9-11 Most, but not
all, mutations associate with macrothrombocytopenia, a
reduction in platelet a-granules, and increased CD34
expression. For some mutations, a reduction in CD42b
expression, paucity of platelet δ-granules, and an increase
in the numbers of morphologically abnormal megakaryo -
cytes in the bone marrow have also been described. Based
on these observations it can be concluded that normal
GFI1B regulates a multitude of megakaryocyte-specific
processes, and that the molecular mechanisms causing the
abnormalities may differ.
GFI1B is a transcriptional repressor containing six C-ter-
minal zinc fingers (in the case of the GFI1B-p37 isoform)
and an N-terminal Snail/GFI1 (SNAG) domain, important
for lysine specific demethylase (LSD1/KMD1A), REST
Corepressor 1 (CoREST/RCOR1) recruitment.13 The
GFI1B-p32 isoform that lacks intact zinc finger 1 and 2,
also associates with LSD1-RCOR1 and is sufficient for
erythropoiesis.12,14 In addition to LSD1, GFI1B recruits his-
tone methyl transferases and histone deacetylases
(HDAC) to target gene promoters and enhancers to induce
transcriptional repression, among which GFI1B itself.15,16
Of the co-factors, LSD1 may be especially important
because the majority (80%) of Gfi1b-bound regions in
murine MEL cells are also enriched for Lsd1 occupancy,
suggesting a strong interdependency.13 LSD1 is an essential
gene in mammalian differentiation and functions, includ-
ing hematopoiesis. In vitro and in vivo Lsd1 knockdown
studies showed that normal granulopoiesis, erythropoiesis
and megakaryopoiesis all depend on Lsd1.13,17,18
Inherited mutations in GFI1B disrupting its DNA bind-
ing zinc fingers, such as GFI1BQ287*, are known to act in a
dominant-negative manner.5 The GFI1B p.Q287* mutation
is located within the fifth zinc finger of GFI1B and leads to
a protein truncated in its DNA-binding region. As a conse-
quence, the ability of GFI1BQ287* to bind GFI1B sequence
motifs is disrupted.8 Importantly, its SNAG domain, cru-
cial for LSD1 binding, remains intact. In this study we
used the dominant-negative GFI1BQ287* mutant to unravel
the mechanism by which it inhibits wildtype GFI1B and
identified GFI1B regulated pathways during megakaryo -
poiesis.
Methods 
Mass spectrometry analysis of GFI1B-interacting 
proteins in MEG-01 cells
MEG-01 cells were lentivirally transduced with FUW, FUW-
GFI1B-green fluorescent protein (GFP) and FUW-GFI1BQ287*-GFP
and nuclear extracts were prepared as described by Dignam et al.19
Label-free GFP-pulldowns were performed using GFP-Trap beads
(ChromoTek) as described by Smits et al.20 Subsequently, the pro-
teins were subjected to on-bead trypsin digestion and peptides
were acidified and desalted using C18-Stagetips.21 Peptides were
recorded with an LC-MS/MS Orbitrap Fusion Tribrid mass spec-
trometer (ThermoFisher Scientific). Raw data were analyzed by
MaxQuant (version 1.5.7.0). Proteins differentially expressed
between empty vector and GFI1B or GFI1BQ287* were determined
using a t-test with a false discovery rate (FDR) <0.01 and a fold
change (FC) >9.2. The stoichiometry of the identified complexes
was determined by dividing the iBAQ intensity in the
GFI1B/GFI1BQ287* samples by the iBAQ intensity in the empty vec-
tor samples. 
Proliferation of GFI1B-transduced MEG-01 cells
MEG-01 cells were retrovirally transduced with pMIGR1-GFI1B
variant-flag-IRES-GFP resulting in mixed cultures of GFP positive
and -negative cells. The GFP% was followed using flow cytome-
try for 26 days. GFP% was normalized to the starting point of the
culture (day 5) using the following formula: GFP% day X/(100 –
GFP% day X))/(GFP% day 5/(100 – GFP% day 5). On day 23,
GFP-positive cells were FACS-sorted to determine total and
endogenous GFI1B expression using quantitative real-time poly-
merase chain reaction analysis. 
Primary megakaryocyte cultures
CD34+ hematopoietic stem and progenitor cells were isolated
from mobilized peripheral blood of healthy donors. Informed
consent was given in accordance with the Declaration of Helsinki
and the Dutch national and Sanquin internal ethical review
boards. CD34+ cells were differentiated to megakaryocytes in
modified Iscove modified Dulbecco medium (HEMAdef)22 sup-
plemented with 50 ng/mL stem cell factor, 50 ng/mL throm-
bopoietin, 1 ng/mL interleukin-3 and 20 ng/mL interleukin-6 for
4 days, followed by culture in 50 ng/mL thrombopoietin and 10
ng/mL interleukin-1β for 7 more days (Peprotech).23 Where indi-
cated, 4 µM GSK-LSD1 (Sigma) was added subsequently and
cells were cultured for an additional 2-6 days depending on the
read out (2 days: expansion, CD34 and CD42b expression; 2-6
days: prolonged effect on CD42b expression and proplatelet for-
mation).
Proteomics mass spectrometry analysis of platelets
and megakaryocytes
Blood was taken from healthy donors and patients to generate
induced pluripotent stem cells (iPSC) and isolate platelets. The
study was approved by the Medical Ethical Committee of the
Radboud University Medical Center, Nijmegen (2013/064) and
conducted in accordance with the Declaration of Helsinki. The
control iPSC line MML-6838-Cl224 and GFI1BQ287* patient iPSC lines
BEL-5-Cl1 and Cl2 (Online Supplementary Figure S1) were differen-
tiated towards megakaryocytes as described before.25 For label-
free quantification, proteins were reduced, alkylated, trypsin-
digested, desalted and concentrated. Tryptic peptides were sepa-
rated by nanoscale C18 reverse phase chromatography coupled
on-line to an Orbitrap Fusion Tribrid mass spectrometer
(ThermoFisher Scientific) via a nanoelectrospray ion source
(Nanospray Flex Ion Source, ThermoFisher Scientific). All mass
spectrometry data were acquired with Xcalibur software (Thermo
Scientific) and processed with the MaxQuant computational plat-
form, 1.5.2.8. The RAW files, MaxQuant search results, and details
about the settings are available in the PRIDE repository database26
with the dataset identifier PXD009020. 
Statistical analysis
Statistical analysis for non-mass spectrometry experiments was
performed in GraphPad Prism.
For more details see the Online Supplementary Methods.
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Results
GFI1B and GFI1BQ287* interact with the
LSD1-RCOR1-HDAC1/2 complex
Several GFI1B variants have been identified in inherited
bleeding and platelet disorders.5,6,8,9 The majority of the
pathogenic variants, such as GFI1B p.Q287*, result in a
truncation disrupting the DNA binding capacity.
Truncated GFI1B inhibits the wildtype protein in a domi-
nant-negative manner.5,8 With the SNAG domain intact,
we hypothesized that GFI1BQ287* can compete with GFI1B
for the recruitment of epigenetic modifiers. To test this
hypothesis, we first identified proteins interacting with
GFI1B and GFI1BQ287*. To this end, C-terminally GFP-
tagged GFI1B and GFI1BQ287* were expressed in
megakaryo blastic MEG-01 cells. GFP-pulldown followed
by on-bead trypsin digestion and mass spectrometry
analysis identified the following GFI1B interacting pro-
teins: LSD1, RCOR1/3, HDAC1/2, GSE1, HMG20B,
PHF21A, and GFI1 (Figure 1A). Of the detected GFI1B
interactors, LSD1 was most abundant, together with
RCOR1/3 and HDAC1/2 (Figure 1B). The proteins GSE1,
HMG20B, and PHF21A are all known to be subunits of the
LSD1-RCOR-HDAC complex, also known as the CoREST
(RCOR1) complex.27 The identified interactome of
GFI1BQ287* was strongly similar to that of GFI1B, with
ZMYM3 as the only significant differential interactor
(Figure 1C; Online Supplementary Figure S2), indicating that
the DNA-binding defective GFI1BQ287* mutant recruits vir-
tually the same co-factors as GFI1B. 
GFI1BQ287* functions in a dominant-negative manner by
sequestering LSD1
The GFI1B p.Q287* mutation results in an increase in
megakaryocyte expansion in vivo and in vitro.5 To investi-
gate whether sequestering of LSD1 by GFI1BQ287* is impor-
tant for this effect, we introduced a P2A or K8A mutation
in the SNAG domain, previously described to disrupt effi-
cient LSD1 recruitment to GFI1 and GFI1B.13,28 We con-
firmed impaired LSD1 recruitment in GFI1BP2A/K8A-GFP
transduced MEG-01 cells using GFP-trap bead-mediated
pulldown (Figure 1D). Furthermore, GFI1BQ287*, GFI1BP2A
and GFI1BK8A failed to inhibit endogenous GFI1B expres-
sion in MEG-01 cells, in contrast to wildtype GFI1B
(Figure 1E-F). Next, we used MEG-01 as a megakaryoblast
model to study the effect of GFI1BQ287* on cell expansion.
In expansion-competition cultures containing transduced
and non-transduced cells, GFI1B-overexpressing cells were
rapidly overgrown by non-transduced cells, while the
opposite was observed following expression of dominant-
negative GFI1BQ287* (Figure 2A). Thus, forced GFI1B expres-
sion inhibits MEG-01 expansion and dominant-negative
GFI1BQ287* results in enhanced expansion, the latter being
in line with observations in GFI1B p.Q287* affected indi-
viduals. 
To determine whether the interaction with LSD1 is
important for the inhibitory effect on expansion of GFI1B,
we separately introduced the P2A and K8A mutations in
GFI1B. Expression of GFI1BP2A or GFI1BK8A nullified the
inhibitory effect of GFI1B on expansion (Figure 2B,C;
Online Supplementary Figure S3). Thus, an intact LSD1-
interacting SNAG domain is required for both inhibition
of MEG-01 expansion and repression of the endogenous
GFI1B locus.
To investigate whether the LSD1 interaction is relevant
for the dominant-negative effect in MEG-01, we intro-
duced the P2A and K8A mutations into GFI1BQ287*. This
showed that similar levels of ectopic GFI1BP2A+Q287* and
GFI1BK8A+Q287* expression did not affect MEG-01 expansion,
in contrast to GFI1BQ287* (Figure 2D,E; Online Supplementary
Figure S3). Together, these data indicate that GFI1B limits
MEG-01 expansion through the LSD1-interacting SNAG
domain. GFI1BQ287* may affect this function in a dominant-
negative manner by sequestering LSD1.
Chemical disruption of the GFI1B-LSD1 interaction 
in normal megakaryocytes results in abnormalities
seen in GFI1B p.Q287* mutated megakaryocytes 
LSD1 sequestering by GFI1BQ287* in MEG-01 resulted in
enhanced proliferation. To determine whether LSD1
sequestration is relevant for other megakaryocyte abnor-
malities, we inhibited the GFI1B-LSD1 interaction during
megakaryocyte differentiation by treating CD34+ cell-
derived megakaryoblasts with the small molecule GSK-
LSD1. This inhibitor binds covalently to the LSD1 cofac-
tor FAD, and thereby sterically hinders binding of GFI1B.29
We confirmed the disrupted LSD1-GFI1B binding by the
absence of co-precipitated LSD1 upon GFP-trap bead-
mediated pulldown in the presence of GSK-LSD1 (Figure
3A). To study effects on megakaryopoiesis, CD34+ cells
were differentiated towards megakaryocytes in the pres-
ence of GSK-LSD1 for 48 h. Quantification of cell surface
marker expression showed sustained CD34 expression
and impaired CD42b expression compared to the expres-
sion in mock-treated cells (Figure 3B-D). Besides this, a 2-
fold increase in megakaryoblast expansion was observed
in the presence of GSK-LSD1 (Figure 3E). CD42b expres-
sion remained low after 3-6 days of exposure to GSK-
LSD1 (Online Supplementary Figure S4C) and we observed
that these cells were unable to form proplatelets after 6
days (Figure 3F, Online Supplementary Figure S4). These
phenotypes are in line with observations in individuals
with the GFI1B p.Q287* mutation.5 Together with data
presented in the previous section, this strongly suggests
that mutant GFI1BQ287* functions in a dominant-negative
manner by sequestering LSD1, resulting in developmental
megakaryocyte abnormalities. 
GFI1BQ287* induced pluripotent stem cell-derived
megakaryocytic cells show disturbed megakaryocyte
differentiation
The morphological megakaryocyte abnormalities, their
increased expansion, and sustained CD34 expression indi-
cate that megakaryocyte differentiation is severely dis-
turbed in GFI1BQ287*-mutated individuals. As the availabili-
ty of CD34+ progenitors and megakaryocytes from
patients is limited, we generated iPSC lines from a control
individual (MML-6838-Cl2)24 and an individual harboring
the GFI1BQ287* mutation (BEL-5-Cl1/2) to study
megakaryo poiesis in more detail (Online Supplementary
Figure S1). iPSC colonies were differentiated towards
megakaryocytes using a two-dimensional differentiation
protocol.25 May-Grünwald Giemsa-stained cytospins and
flow cytometry revealed enlarged cells with sometimes
polyploidization for control megakaryocytic cells, with
co-expression of CD41a and CD42b confirming
megakaryocyte differentiation (Figure 4A,B). In contrast,
differentiation of GFI1BQ287* iPSC resulted in a homoge-
neous appearance of small, pale cells (Figure 4A). In addi-
tion, GFI1BQ287* iPSC-derived megakaryocytic cells
R. van Oorschot et al.
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Figure 1. GFI1B and GFI1BQ287* interact with the LSD1-RCOR-HDAC complex. (A,C)
Nuclear extracts of MEG-01 cells transduced with empty vector (EV), GFI1B-GFP, or
GFI1BQ287*-GFP were analyzed by mass spectrometry. Statistically enriched proteins
were identified by a permutation-based false discovery rate (FDR)-corrected t-test
(FDR<0.01). The volcano plot shows the difference between label-free quantifica-
tion (LFQ) intensities of the GFI1B-GFP or GFI1BQ287*-GFP pulldown and the EV con-
trol [log2-transformed fold change (FC)] on the x-axis, and the -log10-transformed P-
value on the y-axis. Dotted gray lines represent the statistical cutoffs, which were
chosen such that no proteins were present as outliers on the EV control side of the
volcano plot. The proteins in the upper right corner represent the bait (GFI1B) and
its interactors. We cannot exclude the possibility that we missed interactions due
to steric hindrance by the GFP-tag, especially at the C-terminal end. (B)
Stoichiometry analysis of GFI1B interactors in MEG-01 cells showing relative abun-
dances. Discrimination between GFI1B;GFI1, HDAC1;HDAC2, and RCOR1;RCOR3
was not possible because of the presence of common peptides. The iBAQ value of
each interacting protein is plotted with the value for GFI1B;GFI1 set at 1. GFI1 was
identified as an interactor of both GFI1B (all 3 replicates) and GFI1BQ287* (2 of 3
replicates, therefore filtered out). As peptides common to GFI1B and GFI1 were
included in the normalization this may have affected stoichiometry values. Data
are shown as the mean ± standard deviation of three pulldowns. (D) Western blot
analysis of co-immunoprecipitated (IP) LSD1 after GFP-trap bead pulldown in MEG-
01 cells transduced with GFI1B-GFP (WT), GFI1BQ287*-GFP (Q287*), GFI1BP2A-GFP
(P2A), and GFI1BK8A-GFP (K8A). Non-transduced (NT) cells were used as a negative
control. The upper panel shows LSD1 (~90 kDa) and the lower panel GFI1B vari-
ants-GFP (~58 kDa). The left side of the blot shows LSD1 and GFI1B-GFP expres-
sion in the input samples. (E) Western blot analysis of MEG-01 cells transduced
with EV, and GFI1B-GFP, GFI1BQ287*-GFP, GFI1BP2A-GFP, and GFI1BK8A-GFP stained
with an antibody against GFI1B, identifying both exogenous GFI1B-GFP fusions
(~58 kDa) and endogenous GFI1B (~37 kDa). Actin staining was used as a loading
control. (F) Endogenous GFI1B expression (determined by quantitative polymerase
chain reaction on 5’UTR GFI1B, which is not present in overexpression constructs)
relative to GAPDH expression following exogenous expression of EV or indicated
flag-tagged GFI1B variants in MEG-01 cultures from Figure 2. Results are shown
as the mean ± standard deviation (n=3-11).
A
C
D
B
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F
expressed elevated levels of CD34 in line with primary
GFI1BQ287* megakaryocytes,5 while CD41a and CD42b
expression was not different (Figure 4C-E). Quantification
of the total number of CD41a+ cells between days 14-18 of
iPSC differentiation showed that GFI1BQ287* iPSC produced
55-fold more megakaryocytic cells compared to control
iPSC (Figure 4F), in line with the increased number of
bone marrow megakaryocyte observed in GFI1BQ287*-
affected individuals. Electron microscopy of control and
GFI1BQ287* megakaryocytic cells showed the presence of a-
granules in both conditions (Online Supplementary Figure
S5). Together, these data indicate that the GFI1BQ287* iPSC-
derived megakaryocytic cells resemble micromegakaryo -
cytes that exhibit some phenotypes (CD34 expression,
increased expansion) also observed in affected individuals.  
Identification of GFI1B-regulated processes in early
megakaryocyte differentiation
To determine deregulated protein expression down-
stream of GFI1BQ287*, we compared the proteomes of
GFI1BQ287* iPSC-derived CD41a+ megakaryocytic cells (n=6)
with those of controls (n=6). In total 2,906 proteins were
quantified (Online Supplementary Table S1). We detected
CD34 expression in GFI1BQ287* iPSC-derived cells, but not in
control cells (Online Supplementary Table S1).  The mass
spectrometer was not sensitive enough to detect the lower
CD34 expression on control cells versus GFI1BQ287* cells
observed with flow cytometry. The results confirm the
increased CD34 expression observed in the iPSC model
system and patients’ platelets (Figure 4C). Major platelet
receptors, including glycoprotein (GP)-IB, GPIX, and inte-
grin aIIbβ3, as well as a-granule proteins such as von
Willebrand factor (VWF) and thrombospondin-1 (THBS1),
were not differentially expressed between control and
GFI1BQ287* iPSC-derived megakaryocytic cells. However,
396 proteins were differentially expressed between the
GFI1BQ287* and control iPSC-derived megakaryocytic cells,
of which 252 were upregulated and 144 downregulated
(Figure 5A,B; Online Supplementary Table S1). One of the
most strongly downregulated proteins in GFI1BQ287* iPSC
was the interferon-induced GTP-binding protein MX1,
which was expressed strongly in control iPSC-derived cells
R. van Oorschot et al.
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Figure 2. GFI1B and GFI1BQ287* regulate MEG-01 expansion via LSD1 recruit-
ment. (A) Normalized GFP percentages (GFP%) of MEG-01 cells transduced with
empty vector (EV)-IRES-GFP, GFI1B-IRES-GFP and GFI1BQ287*-IRES-GFP for 26
days (n=8). GFP% were normalized to day 5 after transduction (starting point of
the culture) as described in the Methods. Results are shown as the mean ±
standard error of the mean. (B) Normalized GFP% of MEG-01 cells transduced
with EV-IRES-GFP, GFI1B-IRES-GFP, and GFI1BP2A-IRES-GFP (n=4). (C)
Normalized GFP% of MEG-01 cells transduced with EV-IRES-GFP, GFI1B-IRES-
GFP, and GFI1BK8A-IRES-GFP (n=3). (D) Normalized GFP% of MEG-01 cells trans-
duced with EV-IRES-GFP, GFI1BQ287*-IRES-GFP, and GFI1BP2A+Q287*-IRES-GFP (n=3).
(E) Normalized GFP% of MEG-01 cells transduced with EV-IRES-GFP, GFI1BQ287*-
IRES-GFP, and GFI1BK8A+Q287*-IRES-GFP (n=4). *P<0.05, **P<0.01 ***P<0.001.
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DC
E
but not detectable in GFI1BQ287* iPSC-derived cells (Online
Supplementary Figure S6B). Other proteins related to inter-
feron signaling, i.e. STAT1, IFI16, IFI30, IFI35, IFIT1, IFIT3,
OAS2 and OAS3, were also significantly reduced in
GFI1BQ287* iPSC-derived megakaryocytic cells compared to
controls (Online Supplementary Table S1). Because the con-
trol and GFI1BQ287* lines are derived from different individ-
uals, differences in individual protein expression might be
caused by variation in genetic makeup of the lines. We,
therefore, analyzed gene ontology (GO) terms to identify
multiple differentially expressed proteins assigned to spe-
cific pathways/functions. This identified downregulated
proteins related to diverse functions, including mitochon-
dria, response to stimuli, and transmembrane transport
(Figure 5C; Online Supplementary Table S2). On the other
hand, strongly enriched proteins in the GFI1BQ287* iPSC-
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Figure 3. Chemical disruption of the GFI1B-
LSD1 interaction by GSK-LSD1 recapitu-
lates GFI1BQ287* hallmarks in vitro. (A)
Western blot on co-immunoprecipitated (IP)
LSD1 after GFP-trap bead pulldown in
dimethylsulfoxide (DMSO) control or GSK-
LSD1-treated MEG-01 cells transduced with
GFI1B-GFP (WT). Non-transduced (NT) cells
were used as a negative control. The upper
panel shows LSD1 (~90 kDa) and the lower
panel GFI1B variants-GFP (~58 kDa). The
left side of the blot shows LSD1 and GFI1B-
GFP expression in the input samples. (B)
Cell surface expression of megakaryocyte-
associated markers CD34, CD41a, and
CD42b, to measure megakaryocyte matura-
tion. The presented results are from
megakaryocytic cultures 2 days after addi-
tion of DMSO control or 4 μM GSK-LSD1. (C)
CD34 normalized median fluorescence
intensity (nMFI) from CD34+/CD41a+
megakaryoblasts. (D) Percentage of CD42b
positivity on CD41a+ megakaryoblasts. The
connecting lines (C-D) indicate which sam-
ples are from the same experiment. (E)
Expansion of CD34+/CD41a+ megakaryo -
blasts during 2 days of DMSO control or
GSK-LSD1 treatment. (F) Absolute number
of proplatelet-forming megakaryocytic cells
per view (based on Online Supplementary
Figure S4A,B) 6 days after addition of DMSO
or 4 μM GSK-LSD1 (n=6). *P<0.05,
***P<0.001.
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derived megakaryocytic cells were all members of the
minichromosome maintenance complex (DNA replication
licensing factor proteins, MCM2-7) (Online Supplementary
Figure S6A, D) and structural maintenance of chromosome
proteins (SMC1A, SMC2-4, SMCHD) (Online
Supplementary Table S1), which are required for DNA repli-
cation and chromosome condensation, respectively (Figure
5D; Online Supplementary Table S2). Furthermore, MEIS1, a
key player in megakaryocyte differentiation which is nor-
mally downregulated in the final stages of megakaryocyte
differentiation,30 showed consistent expression in
GFI1BQ287* iPSC-derived megakaryocytic cells while it was
never detected in control iPSC-derived cells (Online
Supplementary Figure S6C). Thus, the GFI1BQ287* protein
influences the expression of a large number of proteins dur-
ing megakaryopoiesis. 
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Figure 4. GFI1BQ287* of induced pluripotent stem cell-derived megakaryoid cells phenocopy disease characteristics. (A) Cytospins of control and GFI1BQ287* induced
pluripotent stem cell (iPSC) lines differentiated towards megakaryocytes (MK) and stained with May-Grünwald Giemsa. Pictures were taken at 40x magnification
using a Zeiss Scope.A1 microscope (Zeiss) and images were processed with Zen blue edition. (B) Representative flow-cytometric analysis of control and GFI1BQ287*
iPSC-derived cells for surface expression of megakaryocyte-associated markers CD34, CD41a and CD42b. (C-E) Normalized median fluorescence intensity (nMFI) of
CD34 (C), CD42b (D) and CD41a (E). (F) Quantification of CD41a+ megakaryocytic cells per seeded iPSC to measure expansion potential. CD41a+ cells were negative
for erythroid, myeloid and endothelial makers indicating that these cells represent true megakaryocytic cells (data not shown) **P<0.01, ****P<0.0001.
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Proteome changes in GFI1B p.Q287* platelets are not
limited to a-granule protein depletion
GFI1BQ287* iPSC-derived megakaryocytic cells show phe-
notypes that indicate aberrant differentiation. With
platelets representing the final stage of megakaryopoiesis,
we asked how this is translated to the platelet proteome.
To identify the deregulated proteins, platelet protein levels
of four GFI1BQ287*-affected individuals were compared to
those of four healthy individuals using label-free quantita-
tive mass spectrometry. Out of 2,550 quantified proteins,
1,005 proteins were differentially expressed between nor-
mal and GFI1BQ287* platelets, with the expression of 395
proteins being reduced and that of 610 elevated in the case
of the GFI1BQ287* mutation (Figure 6A,B; Online
Supplementary Table S3). In line with the reported a-gran-
ule deficiency,5 a-granule proteins such as VWF, THBS1,
and platelet factor 4, showed markedly reduced levels in
GFI1BQ287* platelets (Figure 6C). Of note, NBEAL2, which is
mutated and causative for the a-granule deficiency in clas-
sical gray platelet syndrome,31-33 was not among the pro-
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Figure 5. Differential protein expression between GFI1BQ287* and control induced pluripotent stem cell-derived megakaryocytic cells. (A) Protein levels in control and
GFI1BQ287* induced pluripotent stem cell (iPSC)-derived megakaryocytic cells were determined using label-free quantification (LFQ) and differentially expressed pro-
teins were determined using a two-sided t-test (P<0.05 and s0=0.5). The volcano plot shows the -log10-transformed P-value against the log2 fold change (FC) in relative
protein levels between control and GFI1BQ287* iPSC-derived megakaryocytic cells, with each protein represented by a single point in the graph. Dashed lines represent
the statistical cutoff. A negative FC indicates proteins with reduced levels and a positive FC indicates proteins with elevated levels in GFI1BQ287* iPSC-derived cells. (B)
Heat-map and hierarchical clustering of the 396 differentially expressed proteins between control and GFI1BQ287* iPSC-derived cells. Heat-map colors are based on
the z-scored (log2) LFQ values. Blue shades correspond to decreased expression levels and yellow shades to increased expression levels. Imputed values are shown
in the case a protein was not detected. (C) Enrichment of Gene Ontology (GO) terms based on biological process, molecular function and cellular components was
assessed as described in the Methods section. The overlap heat-map shows significant GO terms related to downregulated proteins in GFI1BQ287* iPSC-derived
megakaryocytic cells. For each cluster, one or two summarizing terms are indicated. For a full list of significant GO terms see Online Supplementary Table S2. (D)
The significant GO terms with corresponding P-values for upregulated proteins in GFI1BQ287* iPSC-derived megakaryocytic cells are shown. 
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Figure 6. Proteins differentially expressed between GFI1BQ287* and control platelets. Platelets from four GFI1BQ287* patients and four healthy individuals were isolated
and protein levels were assessed using mass spectrometry. Differentially expressed proteins were determined using a two-sided t-test (P<0.05 and s0=0.5). (A)
Volcano plot showing the -log10-transformed P-value against the log2 fold change (FC) in relative protein levels between control and GFI1BQ287* platelets. Dashed lines
represent the statistical cutoff. A negative FC indicates proteins with reduced levels and a positive FC indicates increased levels in GFI1BQ287* platelets. (B) Heat-map
with hierarchical clustering for the 1,007 differentially expressed proteins between control and GFI1BQ287* platelets. Heat-map colors are based on the z-scored (log2)
label-free quantification (LFQ) values. Blue shades correspond to decreased expression levels and yellow shades to increased expression levels. Imputed values are
shown in case a protein was not detected. (C) Relative protein levels (log2 LFQ values) of selected α-granule proteins in platelets of healthy controls (circles) and
GFI1BQ287* patients (squares). ANGPT1: angiopoietin-1; FGA: fibrinogen alpha chain; SPARC: secreted protein acidic and rich in cysteine; PF4: platelet factor 4; THBS1:
thrombospondin-1; VWF: von Willebrand factor. (D-E) Gene ontology (GO) term enrichment analysis of the significantly expressed proteins in GFI1BQ287* platelets.
Overlap heat-maps of significant GO terms associated with downregulated (D) and upregulated (E) proteins in GFI1BQ287* platelets. For each cluster, one or two sum-
marizing terms are indicated. For a full list of significant GO terms see Online Supplementary Table S2. 
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teins reduced in GFI1BQ287* platelets, but was in fact mildly
elevated (Online Supplementary Table S3). In addition,
strongly elevated expression of CD34 was observed in
GFI1BQ287* platelets, compatible with findings reported
above and published reports.5,8 Other proteins enriched in
GFI1BQ287* platelets were proteasomal, ribosomal, and
mitochondrial proteins (Online Supplementary Figure S7;
Online Supplementary Table S3). GO terms associated with
downregulated proteins in GFI1BQ287* platelets were
strongly related to platelet functions and a-granules,
including wound healing, chemotaxis, immune response,
and vesicle secretion (Figure 6D; Online Supplementary
Table S2). Proteins whose levels were elevated in GFI1BQ287*
platelets were particularly enriched for GO terms on mito-
chondrial function and the respiratory electron transport
chain (Figure 6E; Online Supplementary Table S2). In addi-
tion, a multitude of other cellular processes associated
with underrepresented (e.g. the Golgi and ER systems,
adhesion, and the cytoskeleton) and overrepresented pro-
teins (e.g. ubiquitination, RNA processing, hematopoietic
differentiation, and several metabolic functions) were
observed (Figure 6D,E; Online Supplementary Table S2).
Thus, in addition to a major reduction in a-granule pro-
teins, GFI1BQ287* platelets exhibit aberrant expression of
many other proteins with various functions.
The GFI1BQ287* platelet proteome resembles that 
of early megakaryoblasts
As both platelets and cultured megakaryocytic cells har-
boring the GFI1BQ287* mutation express the early progeni-
tor marker CD34, we next asked whether GFI1BQ287*
platelets also express other early megakaryocyte proteins
that are normally downregulated upon terminal differen-
tiation. To study this, we compared protein profiles of
healthy maturing megakaryocytes with GFI1BQ287*
patient-derived platelets. To this end, CD34+ cells were
differentiated to megakaryocytes and harvested for mass
spectrometry analysis between days 4 and 14 of differen-
tiation. A total of 3,733 proteins were quantified, of
which 1,668 proteins showed significantly different
expression levels during megakaryocyte maturation
(Figure 7A; Online Supplementary Table S4). Two main
clusters of proteins showed strong upregulation (578 pro-
teins) or downregulation (1,026 proteins) towards the late
stages of megakaryocyte differentiation. Compatible
with the role of megakaryocytes as the platelet progeni-
tor cells, platelet a-granule proteins and receptors were
strongly increased during megakaryocyte differentiation
(Figure 7B,C). GO term analyses showed that upregulated
proteins were indeed strongly related to platelet biogene-
sis and function, including wound healing, (a) granules,
the cytoskeleton, and cell activation (Online Supplementary
Figure S8A; Online Supplementary Table S2).
Downregulated proteins were associated with several
GO terms related to ribosome function, RNA processing,
DNA replication (including the MCM proteins) and other
metabolic and biosynthetic processes (Online
Supplementary Figure S8B; Online Supplementary Table S2).
Next, the over- and underrepresented proteins in
GFI1BQ287* platelets were compared with the protein pro-
files of the maturing megakaryocytes. The majority of
downregulated proteins in GFI1BQ287* platelets showed a
clear pattern of upregulation in differentiating
megakaryo cytes (~80%) (Figure 7D), whereas the pro-
teins that showed upregulation in GFI1BQ287* platelets
were generally downmodulated during megakaryocyte
differentiation (~60%) (Figure 7E). As platelets represent
the terminal stage of megakaryocyte maturation, our pro-
teomic data show that GFI1BQ287* platelets resemble poor-
ly differentiated megakaryocytes. 
Discussion
The work presented here furthers our understanding on
deregulated and disease-causing processes in GFI1B-related
bleeding and platelet disorders. Earlier we proposed that
GFI1BQ287*, observed in individuals with an inherited bleed-
ing diathesis, may inhibit the function of wildtype GFI1B
in a dominant-negative manner by sequestering co-repres-
sors.5 Indeed, mutant GFI1BQ287* still interacts with LSD1
and its associated proteins in MEG-01 cells. Unlike GFI1B
causing a decrease in proliferative capacity, forced expres-
sion of GFI1BQ287* in MEG-01 cells resulted in increased pro-
liferation. This increase was nullified upon introduction of
single point mutations in GFI1BQ287* which abrogate the
interaction with LSD1. In line with these findings we
observed that disruption of the GFI1B-LSD1 interaction,
using GSK-LSD1, induces GFI1BQ287*-like phenotypes in
CD34+ cell-derived megakaryocytes, including the down-
regulation of CD42b. Yet, GFI1BQ287* iPSC-derived
megakaryocytes did not show impaired CD42b expres-
sion. This could be explained by variation in CD42b
expression observed in affected individuals, with highest
levels being comparable to those observed in non-affected
individuals.5 Alternatively, this may be explained by differ-
ences in in vivo and in vitro differentiation cues.
Nevertheless, we propose that GFI1BQ287* inhibits wildtype
GFI1B by inhibiting LSD1-dependent processes through
competitive sequestration of LSD1 and its binding part-
ners. 
The relevance of the GFI1B-LSD1 interaction in
megakaryoblast expansion is substantiated by observa-
tions in mice following in vivo Lsd1 silencing. This resulted
in Meis1 overexpression and increased megakaryocyte
numbers in the bone marrow as well. Of note, here we
found MEIS1 only in GFI1BQ287* iPSC-derived megakaryo -
cytic cells but not in control iPSC-derived cells, indicating
elevated expression in the former. Interestingly, Lsd1-
silenced mice also exhibited megakaryocyte abnormali-
ties, thrombocytopenia and a reduction of platelet gran-
ules, similar to the phenotypes of patients harboring the
dominant-negative GFI1BQ287* mutation.18 This could mean
that the functional interplay between GFI1B and LSD1 is
not limited to controlling megakaryoblast proliferation
and differentiation, but that it is also required for terminal
maturation and the generation of granules and platelets. In
addition, this interplay is not restricted to megakary-
opoiesis, but has also been shown to be essential for the
transition of endothelial to hematopoietic stem cells and
erythrocyte development.13,14,34 
In addition to GFI1BQ287*, two other truncating GFI1B
mutations that disrupt the DNA binding domain have
been identified, G272fs8 and H294fs,6 both of which lead
to a similar bleeding and platelet disorder. These GFI1B
mutations also act in a dominant-negative manner. Thus,
LSD1 sequestration by mutant GFI1B that cannot bind its
transcriptional targets may be a general mechanism
through which a collection of GFI1B mutations acts. In
these cases, the mutation is present in both GFI1B iso-
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forms and they will inhibit wildtype GFI1B-p37 and
GFI1B-p32. However, because the expression of GFI1B-
p32 is much lower than that of GFI1B-p37,14 LSD1 seques-
tration by GFI1BQ287*-p32 will be less than that by
GFI1BQ287*-p37. The molecular mechanisms causing
megakaryocyte and platelet defects for other reported
GFI1B mutations are likely different because the DNA
binding and LSD1-interacting domains remain intact in
these mutants.
We observed that GFI1B mainly associates with the
LSD1-RCOR-HDAC repressor complex (also called BRAF-
HDAC complex in neural development) containing LSD1,
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Figure 7. The GFI1BQ287* platelet proteome reveals impaired megakaryocyte differentiation. The proteome of in vitro-differentiating megakaryocytes (MK) was ana-
lyzed by label-free mass spectrometry (see Methods). Differentially expressed proteins were determined using analysis of variance (false discovery rate <0.05,
s0=0.5). (A) Heat-map with hierarchical clustering of the 1,668 proteins showing significantly different expression between any of the analyzed days of MK differen-
tiation, i.e. day 4, 5, 6, 7, 8, 9, 10, 11, and 14 of differentiation (from left to right) with three replicates per day of culture. Relative protein levels [z-scored log2 label-
free quantification (LFQ)] are shown with imputed values in the case a protein was not detected. (B) Expression levels in cultured MK of platelet a-granule proteins
during MK differentiation. (C) Expression levels in cultured MK of platelet receptors during MK differentiation. (D-E) Relative expression levels in cultured MK of pro-
teins with significantly increased or decreased levels in GFI1BQ287* platelets: 272 of the 395 downregulated proteins (D) and 503 of the 610 upregulated proteins (E)
in GFI1BQ287* platelets were identified in the MK. Magenta/blue shades in the heat-maps correspond to decreased expression levels and yellow/orange shades to
increased expression levels; a gray color indicates that a protein was not identified in a given MK sample (Panels D and E only). THBS1: thrombospondin-1; VWF: von
Willebrand factor; PF4: platelet factor 4; ANGPT1: angiopoietin-1; SELP: selectin P; ITGA2B: integrin subunit alpha 2b; ITGB: integrin subunit beta; CD36: cluster of
differentiation 36; GP1BA: glycoprotein Ib platelet subunit alpha; GP9: glycoprotein 9.
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RCOR1, HDAC1/2, PHF21A (BHC80), and HMG20B
(BRAF35).35 The other proteins found, GSE1, RCOR3, and
ZMYM2/3, are also known LSD1 interactors,36 of which
ZMYM2/3 have not been reported in complex with GFI1B
before. ZMYM3 was identified as the only significantly
different interacting protein between GFI1B and
GFI1BQ287*. Whether this is relevant for disease pathogene-
sis remains to be seen. Most interactors (LSD1, RCOR1/3,
HDAC1/2, GSE1, ZMYM2/3) are detected in differentiat-
ing megakaryocytes as well (Online Supplementary Table
S4), suggesting that they may be relevant for megakaryo -
cyte development. 
Comparison of the proteome of different iPSC-derived
megakaryocytic cell cultures showed a uniform expres-
sion pattern in GFI1BQ287* cells compared to wildtype cells.
The latter might be more variable due to differences in
megakaryocytic differentiation stages between cultures.
GFI1BQ287* megakaryocytes exhibit a more uniform,
micromegakaryocyte-like appearance, suggesting that
they are arrested before polyploidization. This is in con-
trast with megakaryocytes observed in GFI1BQ287* individ-
uals5 and conditional GFI1B knockout mice,37 in which a
block after polyploidization but before cytoplasmic mat-
uration is observed. Possibly, environmental cues that are
absent in in vitro cultures may stimulate differentiation of
GFI1BQ287* megakaryocytes in vivo.
In GFI1BQ287* iPSC-derived megakaryocytic cells we
observed a downregulation of downstream interferon-γ
signaling targets, such as STAT1, MX1, IFI16, IFI30, IFI35,
IFIT3, OAS2 and OAS3. Interferon-γ and its downstream
effector STAT1 stimulate megakaryocyte differentiation
and platelet production. STAT1 promotes polyploidiza-
tion and loss of STAT1 in JAK2V617F mice resulted in
reduced platelet numbers through interference with
megakaryocyte development.38,39 The failure to activate
interferon target genes in GFI1BQ287* megakaryocytes may
inhibit differentiation and explain the micromegakaryo -
cyte-like appearance of iPSC-derived megakaryocytes. 
GFI1BQ287* iPSC-derived megakaryocytic cells further
revealed significantly increased levels of the MCM com-
plex and MEIS1. This might be relevant as the MCM
complex is involved in DNA replication/cell cycle pro-
gression and, in accordance with several studies,40,41 we
observed that MCM proteins are downregulated upon
megakaryocyte differentiation (Online Supplementary
Figure S6D).40,41 In addition, we showed earlier that forced
MEIS1 expression in CD34+ cells results in larger and
more colonies in colony-forming unit-megakaryocyte
assays.30 Thus, failure of downmodulation of DNA repli-
cation-associated genes by GFI1B as a consequence of
sequestration of LSD1 and associated proteins by
GFI1BQ287* might contribute to increased proliferation and
lack of polyploidization.
The platelets of GFI1BQ287* patients showed a major
reduction in a-granule proteins, ranging from a mild <2-
fold decrease (e.g. for SPARC, fibrinogen a and β chains)
to a severe >10-fold depletion (e.g. for VEGF and P-
selectin). To our surprise, NBEAL2 showed significantly
increased expression in both platelets and iPSC-derived
cells harboring the GFI1BQ287* mutation. Inactivating muta-
tions in NBEAL2 cause recessive gray platelet syndrome, a
bleeding disorder characterized by a severe paucity in a-
granules.31-33 Although its exact function is still unclear,
NBEAL2 is thought to be required for the biogenesis
and/or retention of a-granules in megakaryo cytes.42-44
Other proteins with putative roles in a-granule formation,
such as VPS33B45 and VIPAS39,46 and proposed NBEAL2
interactors DOCK7, SEC16A and VAC1447 were mostly
unaffected in both GFI1BQ287* platelets and iPSC-derived
cells, except SEC16A and VAC14, which showed a mild
(<2-fold) decrease and increase in GFI1BQ287* platelets,
respectively. Possibly, these proteins are under differential
control of GFI1B. In contrast to the GFI1BQ287* platelets
there was no change in a-granule proteins observed in
GFI1BQ287* iPSC-derived megakaryocytic cells. This could
suggest that the observed a-granule defect in primary
GFI1BQ287* platelets may not be caused by defective protein
expression, but possibly originates from defective trans-
port from proteins to a-granules and/or defective traffick-
ing of a-granules to proplatelets.
In addition to the reduction in a-granule proteins, the
proteome of GFI1BQ287* platelets showed other abnormali-
ties including increased expression of ribosomal, proteaso-
mal and mitochondrial proteins. These findings imply that
proplatelet-forming megakaryocytes of GFI1BQ287* patients
may differ from normal mature megakaryocytes at the
metabolic level. Some of the upregulated platelet proteins,
in particular the ribosome subunits, showed significant
downregulation during in vitro megakaryocyte differentia-
tion, in line with the presumed maturation defect in
GFI1BQ287* megakaryocytes. Indeed, early megakaryocytes
exhibit high protein synthesis rates to support their
increasing cellular mass, while this ceases in the final
stages of maturation.48 In addition, proteasomal and mito-
chondrial activities are closely related to the regulation of
cell fate decisions.49,50 Highly proliferating cells, including
cancer cells and (hematopoietic) stem cells, show distinct
mitochondrial activities, and proliferating hematopoietic
stem cells have increased mitochondrial mass compared
to quiescent hematopoietic stem cells.51,52 Thus, the
increase in mitochondrial proteins might support the
hyperproliferation of GFI1BQ287* megakaryocytes.
In conclusion, GFI1B regulates protein expression in
megakaryocytes through recruitment of the LSD1-
RCOR-HDAC co-repressor complex. During megakaryo -
poiesis many proteins are regulated by GFI1B, which
associate with expected but also new processes.
GFI1BQ287* may inhibit GFI1B by specifically sequestering
the LSD1-RCOR-HDAC complex, making it less avail-
able for GFI1B. The normal and affected megakaryocyte
and platelet proteomes reported here may serve as a ref-
erence for better understanding of other platelet disorders
and the molecular pathways that drive megakaryopoiesis
and platelet development.
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